MedTrace Logo

Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

NCT06379958 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-08-09

No results posted yet for this study

Summary

A DDI study consisting of 4 parts conducted as an open label, fixed sequence study in healthy adult subjects.

Conditions

  • Pharmacokinetics

Interventions

DRUG

leramistat 40mg

Oral capsule

DRUG

Itraconazole 200 mg

Oral capsule

DRUG

Phenytoin 100 Mg Oral Capsule

Oral capsule

DRUG

Simvastatin 40mg

Oral capsule

DRUG

Upadacitinib 15 MG

Oral Capsule

Sponsors & Collaborators

  • Modern Biosciences Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-08
Primary Completion
2024-09-30
Completion
2024-09-30
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06379958 on ClinicalTrials.gov